Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib For Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome.

Autor: Elghawy O; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Yang AG; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Sussman JH; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Thomas CJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Carter JS; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Kim E; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Rook AH; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Chung J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Villasenor-Park J; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Plastaras JP; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., LaRiviere M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Hubbeling H; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Chelius M; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: stefan.barta@pennmedicine.upenn.edu.

Publikováno v: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Nov 16. Date of Electronic Publication: 2024 Nov 16.

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.

Autor: Epperla N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT., Zayac AS; Department of Medicine, Lifespan Cancer Institute, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI., Landsburg DJ; Division of Hematology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Bock AM; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.; Division of Hematology, Mayo Clinic, Rochester, MN., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN., Ayers EC; Division of Hematology/Oncology, University of Virginia, Charlottesville, VA., Girton M; Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA., Hu M; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Beckman A; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN., Li S; Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Medeiros LJ; Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Chang JE; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI., Kurt H; Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, RI., Sandoval-Sus J; Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL., Ansari-Lari MA; Department of Pathology, Hematopathology, Memorial Health System-Moffitt Cancer Center, Hollywood, FL., Kothari SK; Department of Medicine, Yale University School of Medicine, New Haven, CT., Kress A; Department of Medicine, Yale University School of Medicine, New Haven, CT., Xu ML; Department of Pathology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT., Torka P; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Sundaram S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Smith SD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, University of Washington, Seattle, WA., Naresh KN; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA., Karimi Y; Division of Hematology-Oncology, University of Michigan Health, Ann Arbor, MI., Bond DA; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Evens AM; Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Naik SG; Department of Medicine, Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA., Kamdar M; Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO., Haverkos BM; Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Denver, CO., Karmali R; Division of Hematology and Oncology, Northwestern University, Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center, Chicago, IL., Farooq U; Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA., Vose JM; Department of Medicine, University of Nebraska Medical Center, Omaha, NE., Rubinstein P; Department of Hematology-Oncology, University of Illinois-Chicago, Chicago, IL., Chaudhry A; Department of Hematology-Oncology, University of Illinois-Chicago, Chicago, IL., Olszewski AJ; Department of Medicine, Lifespan Cancer Institute, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.

Publikováno v: Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5355-5364.